Table 3.
Overall publication status of human drug studies by study outcome. Figures are number of studies; percentage based on proportion of study outcome with given publication status (95% CI), unless stated otherwise
| All studies | Positive | Negative | Mixed | Non-comparative | |
|---|---|---|---|---|---|
| Submitted: | |||||
| Published* | 751; 71 (68 to 73) | 212; 66 (61 to 71) | 119; 77 (70 to 83) | 40; 77 (64 to 86) | 380; 71 (67 to 75) |
| Pending | 100; 9 (8 to 11) | 32; 10 (7 to 14) | 13; 8 (5 to 14) | 4; 8 (3 to 18) | 51; 10 (7 to 12) |
| Rejected | 53; 5 (4 to 6) | 11; 3 (2 to 6) | 10; 6 (4 to 11) | 5; 10 (4 to 21) | 27; 5 (3 to 7) |
| Abstract only | 77; 7 (6 to 9) | 16; 5 (3 to 8) | 13; 8 (5 to 14) | 3; 6 (2 to 16) | 45; 8 (6 to 11) |
| Not submitted | 83; 8 (6 to 10) | 50; 16 (12 to 20) | 0; 0 (0 to 2) | 0; 0 (0 to 7) | 33; 6 (4 to 9) |
| Mean (IQR) time to submission (days)† | 537 (396-638) | 504 (343-601) | 535 (408-612) | 538 (366-640) | 543 (427-674)* |
| Mean (IQR) time to publication (days)‡ | 823 (650-1063) | 774 (628-949) | 876 (708-1203) | 824 (694-1041) | 833 (650-1103)* |
IQR=interquartile range.
*Includes 48 studies accepted but not yet published as of data cut-off date.
†Based on 867 studies with study end and subsequent submission dates.
‡Based on 670 studies with study end and subsequent publication dates.